Forte Biosciences, Inc. (FBRX) Research

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Market snapshot

Symbol
FBRX
Price
$17.85
Day change
+1.48%
Market cap
$247.9M
P/E ratio
-41.97x
52-week range
9.1-35.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$65.00

Peer companies

  • Actuate Therapeutics Inc (ACTU)
  • Alector, Inc. (ALEC)
  • Applied Therapeutics, Inc. (APLT)
  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Cardiff Oncology, Inc. (CRDF)
  • Elicio Therapeutics, Inc. (ELTX)
  • Fate Therapeutics, Inc. (FATE)
  • Molecular Partners AG (MOLN)

Recent insider activity

  • Riley Antony A — A-Award (22000 shares) on 2026-06-16
  • Wagner Paul A. — A-Award (500000 shares) on 2026-06-16
  • Doberstein Stephen K — A-Award (18353 shares) on 2026-05-29
  • Kapoor Shivpreet Singh — A-Award (18353 shares) on 2026-05-29
  • VINCENT RICHARD G — A-Award (18353 shares) on 2026-05-29

Open Forte Biosciences, Inc. (FBRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.